The research is being carried out by Cats Protection, RSPCA, PDSA, Wood Green The Animal Charity, Blue Cross, Celia Hammond Animal Trust, Battersea, The Mayhew Animal Home, SSPCA and International Cat Care, with support from Bristol University.
The study involves four short (<15 minute) questionnaires spread over a 6-month period, for which you could also win a £50 voucher.
Click here to find out more and sign up www.surveymonkey.co.uk/r/neutering
A survey carried out by Rachel Crowe BSc PhD in association with Virbac Animal Health and VetSurgeon.org has revealed what veterinary surgeons in the UK expect from pharmaceutical companies and other suppliers.
The survey considers a number of different aspects of the relationship between vets and pharmaceutical companies, from the importance of quality products through to the question of what vets expect from company representatives.
Chris Liggett, Marketing Director at Virbac UK said: "The findings of this survey offer a fascinating insight into the relationship between veterinary practices and their suppliers. In some ways they confirm what we should all already know - that the quality of a company's product range is paramount and that representatives play a key role as ambassadors for our businesses - but the growing importance to vet practices of working with drug companies that provide a complete package of products and services is worthy of note."
The full report is available to download here.
The committee heard five charges against Dr Davies at a resumed hearing of an inquiry which was originally adjourned in January and then July 2018. The decision was made, at both the 2018 hearings, to postpone the final decision on the sanction.
The first two charges against Dr Davies related to convictions for drink driving in March 2014 and October 2015 for which she received driving bans of 17 and 45 months.
The third charge related to her breaching a number of undertakings she had entered into as part of the College’s Health Protocol, including her consuming alcohol on four occasions between May 2015 and January 2016 and missing a pre-arranged appointment with a consultant psychiatrist appointed.
The fourth and fifth charges related to being under the influence of alcohol on three occasions while she was on duty as a veterinary surgeon in December 2016 which was also in breach of her undertakings under the Health Protocol.
At Dr Davies' first Disciplinary Committee hearing in January 2018, she admitted all five charges against her and also accepted that her conduct was disgraceful conduct in a professional respect.
The Committee accepted her admissions and found, with the exception of one allegation, that her conduct was disgraceful in a professional respect.
At the conclusion of its hearing on 23 January 2018 the Committee decided to postpone its decision regarding sanction for six months on the basis of Dr Davies’ entering into undertakings, including not to practise veterinary surgery and to remain abstinent from alcohol during the period of postponement and to undergo blood and hair tests for alcohol consumption every two months.
At the resumed hearing on 30 July 2018, Dr Davies’ Counsel submitted on her behalf that she wished to return to practise and the Committee reviewed evidence that she provided to demonstrate she had complied with her undertakings.
However, the Committee retained concerns about Dr Davies' return to practise and therefore required her to identify a veterinary surgeon who would agree to act as her mentor, noting that the mentor would have to be acceptable to the College as someone suitable to act in that capacity.
The Committee also required the continuation of the requirements for abstinence from alcohol and the programme of blood and hair testing.
A further requirement of the Committee was that Dr Davies should make a disclosure to any new employer of her appearances before the Committee in January 2018 and in July 2018 and of the decisions it made.
The final requirement of the Committee was that the respondent should not accept a ‘sole charge position’ at any time during her employment during this next period of postponement of sanction. The Committee then directed that the hearing be postponed for a further 12 months.
The Disciplinary Committee resumed its inquiry on 7th August 2019, when Dr Davies submitted documentary proof and medical records to demonstrate she had complied with all her undertakings given at the last hearing. The Committee also heard from Dr Davies’ appointed veterinary mentor who provided a statement that concluded that she no longer needed monitoring or supervision.
The Committee then considered what sanction to impose on Dr Davies.
Ian Green, chairing the Committee and speaking on its behalf, said: "The view of the Committee is that the respondent has to date overcome her addiction to alcohol and, given that her competence as a practising veterinary surgeon is not disputed, that she should therefore be permitted to return to her chosen profession. However, in the judgment of this Committee the seriousness of the offences to which the Respondent has pleaded guilty means that a sanction of “No Further Action” cannot be justified."
The Committee therefore decided that the most proportionate sanction was for Dr Davies to be reprimanded as to the conduct she admitted at previous hearings and that she be warned as to her future conduct.
Ian added: "The respondent must understand that she has been given an opportunity to prove that, for the remainder of her time in practice, she can meet the high standards expected of all registered veterinary surgeons from both other practitioners and from members of the public who entrust the care and treatment of their animals to members of this profession."
York-based Alstoe Animal Health, maker of Gleptosil and Vetergesic, has been acquired by French company Sogeval, a leading supplier of companion and livestock animal products.
Established in 1994, Alstoe was privatelv owned by the two original partners, John Nellis and lan Ryder.
For the last five years the company has been working with Sogeval to develop flavoured tablet pharmaceutical brands from Sogeval whilst the two companies have collaborated to make Vetergesic successful in France.
The business will continue to trade from the current premises for the foreseeable future and says it will maintain its high standard of customer service and product supply.
John Nellis said: "lt will be business as usual. We look forward to continued sales growth for our existing brands and the introduction of exciting new products in the future".
Dr. lan Ryder said: "Our companies have worked very well together in the past. The acquisition will bring fresh impetus to the business and ensure continued growth"
The current Alstoe team remains in place to assist with any enquiries. For further information contact info@alstoe.co.uk or telephone: 01347 878605
The Kennel Club is calling on the profession to support Get Fit With Fido, its new campaign to help tackle the growing dog obesity crisis by educating owners about the range of different ways to get fit with their dogs..
In addition to the education campaign, Get Fit With Fido also includes a challenge that rewards the dog and dog owner who jointly lose the most weight, and the dog owner and dog who individually lose the most weight, as a result of exercising together. Prizes include a one night stay at the dog friendly, 4* boutique townhouse hotel Flemings Mayfair; a luxury dog bed from Charley Chau and Champagne Afternoon Tea for Two at the Milestone Hotel.
All dog owners who enter Get Fit With Fido, will receive a 20% discount on Crufts and Discover Dogs tickets; as well as advice, tips and tools for owners.
Veterinary practices are being asked to support the campaign by requesting free flyers and posters from the Kennel Club and then displaying them at reception, or in the waiting room.Caroline Kisko, Kennel Club Secretary, said: "Reports indicate that between 30 and 60% of all dogs are overweight so it is more important than ever we keep our dogs happy and healthy. One of the most serious findings in obesity studies that have proven to be related to being overweight in both humans and dogs is a reduced lifespan. An overweight dog is more likely to die younger than a dog of normal weight.
"The findings are shocking and we are trying to educate as many dog owners as possible and call on vets to spread the message of keeping your dog fit and healthy."
To get involved in Get Fit With Fido and receive free flyers and posters, contact the Kennel Club press office at gfwf@thekennelclub.org.uk
For more information, visit www.thekennelclub.org.uk/getfitwithfido
What is 'quality improvement', you ask? Good question. Sure, it's an improvement in, er, quality. But of what?
'Quality improvement' is a term adopted from the human healthcare sector, variously defined as anything which makes: "healthcare safer, effective, patient-centred, timely, efficient and equitable (NHS)", or "the combined and unceasing efforts of everyone—healthcare professionals, patients and their families, researchers, payers, planners and educators—to make the changes that will lead to better patient outcomes (health), better system performance (care) and better professional development (BMJ)."
The RCVS research project, which is being conducted by RAND EUROPE, will assess current perceptions and adoption of quality improvement in the veterinary profession.
Specifically, it'll look at the drivers, barriers and expectations associated with QI, with the ultimate goal of strengthening the support provided to the profession.
Chris Gush, Executive Director of RCVS Knowledge, said: "We are delighted to be launching this research project with RAND Europe.
"We know that many of our colleagues across the profession have embedded quality improvement into their practice to great benefit, while we are also aware that it can be a challenge to do so all of the time.
"This research will provide an unprecedented body of evidence on the experiences and perceptions of QI, which will be critical to how we work to support the sector in this area going forward."
Integral to the research is a survey which all members of the profession are invited to take part in, here: bit.ly/QIvetsurvey.
The survey will be live for six weeks, closing early April. It takes around ten minutes to complete, with a prize of one £150 Amazon voucher on offer. Responses will be anonymised.
You can read more about Quality Improvement on the RCVS Knowledge website, here: https://knowledge.rcvs.org.uk/quality-improvement/
The British Veterinary Association has welcomed the tightening up of sales of veterinary medicines on the internet but has expressed disappointment that the advertising of antimicrobials to farmers will continue.
The Veterinary Medicines Directorate has today published its response to the public consultation on the Veterinary Medicines Regulations, which are updated every year.
The new Regulations, which come into force in April 2011, introduce new controls on internet pharmacies meaning that only approved websites will be legally allowed to dispense and supply veterinary medicines. The controls will come into force in April 2012 and the BVA supports the use of a logo on approved websites to help consumers buy medicines from reputable sources.
The BVA has previously expressed concern that pet owners could inadvertently buy counterfeit veterinary medicines online and urges veterinary clients to seek advice from their vet and only buy from UK-based companies.
Harvey Locke, President of the BVA, said: "Without proper regulation online pharmacies could be sourcing drugs from overseas and selling counterfeit medicines that look genuine to unsuspecting pet owners. These medicines are placebos at best and dangerous at worst.
"We therefore welcome the VMD's decision to clampdown on irresponsible online retailers and provide a clear logo for approved websites that will give pet owners confidence.
"We have also asked the VMD to put a stop to the increasing problem of prescription fraud and we hope the tighter regulation announced today will be a step towards achieving that aim.
"However, we would urge all pet owners to continue talking to their vet about sourcing medicines from the internet to make sure the right drugs are bought and administered correctly."
In light of increasing concerns about the growth of antimicrobial resistance the VMD's consultation canvassed views on restricting the advertising of antimicrobials to farmers. The BVA says it supported a ban on advertising as a sensible approach to the responsible use of antimicrobials, and is disappointed that the VMD has decided not to go ahead with it. Mr Locke said: "New antimicrobials are heavily advertised by pharmaceutical companies to vets and farmers so it is vital that the message of responsible use is not lost.
"Antimicrobial resistance is a serious issue for both animal and human health and we are disappointed that the VMD is not restricting the advertising of these products to farmers. The pharmaceutical companies must now undertake to advertise responsibly.
"Ultimately, it is the veterinary surgeon who will make the decision on which veterinary products to use and vets and farmers should work together to ensure antimicrobials are used prudently and responsibly."
Norbrook Laboratories has launched powder and paste versions of Noroquin - its glucosamine-based supplement range - for horses.
Noroquin contains the active ingredients glucosamine, chondrotin sulphate, manganese sulphate, zinc sulphate, absorbic acid and N-Acetyl-D-Glucosamine, designed to maintain healthy cartilage, promote joint management and keep horses mobile.
Michelle Jones, Brand Manager at Norbrook said: "In recent years, horses are increasingly competing longer which means maintaining the longevity of the horse is vitally important for long term success. 60% of lameness is related to osteoarthritis and is regarded as the major cause of disability in the athletic horse.
"With increasing reliability on nutritional supplements and concerns from horse owners about their aging horse, our Noroquin for Horses range can be offered as alternative to traditional pain management products indicated for musculoskeletal ailments or alongside them as a completely safe addition to a joint management programme."
Michelle added: "The Noroquin paste for horses is a highly palatable apple flavored paste that can be fed directly to the horse as a tasty treat and offers an alternative to traditional methods while the Noroquin powder for Horses is a highly palatable powder that can be mixed with food. The product is available in handy single-use sachets for accurate dosing and waterproof 1kg tubs."
Noroquin Powder and Paste for Horses joins the newly launched tasty tablets for dogs and cats and powder for cats in the Noroquin range. It is available from wholesalers.
Norbrook Laboratories has launched Norfenicol Solution for Injection (florfenicol), a broad spectrum antibiotic licensed for the treatment of pneumonia in cattle and pigs.
Dr Barry McInerney, Norbrook's GB Veterinary Advisor said: "With many farmers preparing for winter housing, the launch of Norfenicol is timely as pneumonia represents the most common disease of housed cattle in the UK costing the agricultural industry an estimated £80m per year. Norfenicol is an easy to inject, cost effective treatment of pneumonia which kills bacteria quickly, and is available in a durable plastic bottle. Studies have shown florfenicol, the active ingredient in Norfenicol, to have a high bacteriological and clinical efficacy (100% and 96% respectively) against susceptible bacteria in the treatment of calf respiratory tract diseases."
Norfenicol is indicated for the treatment of bacterial respiratory disease in cattle associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somniand for the treatment of acute outbreaks of respiratory disease caused by strains of Actinobacillus pleuropneumoniae, and Pasteurella multocida in swine.
Dr McInerney added: "NSAIDs have also been shown to be a beneficial ancillary therapy in treating bacterial pneumonia, to alleviate pain as well as to reduce inflammation and pyrexia. Norbrook has a range of NSAID products which are available as an adjunctive treatment for pneumonia in cattle, including Loxicom 20 mg/ml solution for injection for cattle, pigs and horses."
For further product information, visit www.norbrook.com
The Cheshire-based specialist referral centre provides advanced surgical procedures and specialist veterinary support to practices in north west England and north and mid-Wales.
Its specialist disciplines include orthopaedics, soft tissue surgery, a specialist diabetes clinic, spinal surgery, anaesthesia and intensive care, cardiology, diagnostic imaging, pain management, neurology (medical and surgical), oncology and internal medicine.
Liz Cousins, Northwest's Hospital Manager said: "Following our recent brand transition from Northwest Surgeons to Northwest Veterinary Specialists we are delighted to receive this accreditation.
"The scheme examines every part of what we do, from customer experience, equipment and facilities right through to clinical governance. In a hospital with more than 85 colleagues, that’s a lot of work to do to meet the high standards.
"Our new brand name reflects the range of specialist services we offer and this accreditation gives confidence to fellow veterinary surgeons and pet owners that we really do offer the very best specialist care for pets.
"We continually strive for excellence across the business, and this is another way of demonstrating just how good the specialists are at Northwest Veterinary Specialists."
Picture shows: Matt Gurney, European Veterinary Specialist in Anaesthesia and Analgesia (centre) with Kathryn Humphreys, Head of Nursing, (right), Jenny Pearson, support Services Manager, (left) with the RCVS Hospital Accreditation.
The first, which covers three topics: canine uveitis, canine glaucoma and non-healing corneal ulcer, is for the entire practice. It normally costs £95 per practice, but for VetSurgeon.org members, it's £70.
To book, visit: https://docs.google.com/forms/d/e/1FAIpQLScSSbUDCcC53cvPJtj1oPkJFEoDjJ3Tdij_y9iFtr7emBvkoQ/viewform?usp=pp_url
The second course is 'Ophthalmic Examination in the Dogs and Cats', which costs £25 for VetSurgeon.org members, that is reduced to £15 per person.
To book, visit: https://docs.google.com/forms/d/e/1FAIpQLSfnBizM5NmFGwWeDqtdXy9zCq8KdFgGI2e5D8pjuWOTuPln0Q/viewform?usp=pp_url
Originally from Belgium, Tamir, who qualified at Glasgow in 2001, started Vision Vet in 2009 and gained his National French Certificate in Ophthalmology (broadly equivalent to the UK Cert) in 2011.
https://www.vision-vet.co.uk
The RCVS is seeking feedback on a new draft Code of Professional Conduct.
The new Code, which would replace the existing RCVS Guide to Professional Conduct for Veterinary Surgeons, has been produced by a Working Party set up by the RCVS Advisory Committee to review the Guides for both veterinary surgeons and veterinary nurses.
According to the College, the purpose of the review, which last took place over a decade ago, is to ensure guidance to the profession and the public is clear. For example, using consistent language to distinguish between what must be done and what is advised.
The RCVS says the new Code is a short, principles-based document using the Federation of Veterinarians of Europe's Code of Conduct as the starting point. It will be supported by additional advice on specific areas of veterinary practice or issues, for example, clinical governance. It also includes:
Clare Tapsfield-Wright, Chairman of the Guides Review Working Party said: "Over the decade or so since it was last reviewed, not only has the Guide become unwieldy in places, but the way that regulators in general publish professional conduct rules has changed. Our draft new Code aims to clarify matters and bring us into line with best practice elsewhere.
"Animal owners are increasingly keen to understand the basis of what the veterinary profession considers to be good professional conduct. The new simplified Code should assist with this understanding."
The new Code, together with the consultation paper, can be downloaded at http://www.rcvs.org.uk/codeconsultation
Comments, which are welcomed from the profession and the public, should be sent by email to Christopher Murdoch, Secretary to the Guides Review Working Party, at c.murdoch@rcvs.org.uk by Friday, 24 June 2011.
A separate document is under development for veterinary nurses, which will share broadly similar underlying principles and will be the subject of its own consultation.
Merial Animal Health has announced the launch of its new feline vaccine Purevax Rabies in the UK and Ireland.
Merial says the product offers a simple but elegant solution to rabies vaccination, without the need for adjuvant. According to the company, the non-replicative vector is processed by the cat's immune system in the same way as a live virus, triggering both a powerful cell mediated and humoral response without the need for adjuvant. However, because the vector cannot replicate effectively in mammalian cells, there is no risk of any reversion to virulence.
Merial's Veterinary Technical Manager Kevin Whelan, said: "This is a perfect complement to our existing range of advanced technology vaccines, which already offer the benefits of highly effective protection, including updated FCV strains, without the need for adjuvant. It also represents Merial's continued commitment to the development of innovative products for the animal health market".
The vaccine is licensed for use in cats from 12 weeks of age, and administration of a single injection has been shown to provide protection against disease.
Contact your local Merial Representative or the Merial Technical Support line on 0870 6000 123 for further information.
Matt has taken over as hospital director from David Walker, who has now moved to the role of referrals managing director in the south of the UK for Linnaeus.
Matt said: “I certainly have some big shoes to fill but working as clinical director alongside David was a great grounding and we work well together.
“Essentially, I was his running mate back then but now I am stepping up to take on the main role, with all the additional responsibilities it entails, and I’m determined to make it my own.
“I know I have the drive, the desire, the clarity of purpose and the dedication to succeed.
"I also know what an incredible operation I have inherited from David.
“One of the key things about Anderson Moores is that every member of the team works together in the same location to support every aspect of a pet’s treatment and recovery, so whatever service they may need is all available under the same roof.”
www.andersonmoores.com/homewww.zeropainphilosophy.com
The survey is open to all veterinary surgeon members and participants will be entered into a free prize draw to win £500 of BEVA CPD vouchers.
As we all know, antibiotic resistance is increasing throughout human and veterinary medicine, and there are few new antibiotics being produced. As BEVA says, it’s therefore imperative for vets to protect the usage of antimicrobials to maintain their effectiveness for the future.
To that end, the purpose of the survey is to help fill in gaps in knowledge about how antimicrobials are being used and also the current landscape of resistant infections encountered in equine practice.
The survey has been designed by Amie Wilson and Dr Gina Pinchbeck at the University of Liverpool and Tim Mair the incoming President of BEVA.
Tim said: "This survey will assess any changes in prescribing of antimicrobials in equine practice since the last survey in 2009. In addition, we will collect data on the current frequency and types of antimicrobial resistant infections seen by clinicians in all areas of equine practice and what infection control and audit practices are currently using to combat this."
The survey results should lead to a greater understanding of the role of antimicrobial treatment in the overall epidemiology of antimicrobial resistance in horses and will help protect antibiotics for the future of equine and human health.
To take part in the survey, visit: https://liverpool.onlinesurveys.ac.uk/beva-questionnaire-2019-final
The results will be announced to coincide with European Antibiotic Awareness Day on 18 November 2019.
If you have any questions about the survey you can contact the researchers direct: Amie Wilson, University of Liverpool A.wilson3@liv.ac.uk; Dr Gina Pinchbeck, University of Liverpool ginap@liv.ac.uk; Tim Mair, British Equine Veterinary Association tim.mair@btinternet.com
The reports summarise the results of two surveys that were conducted between July and August last year.
Of the 28,718 veterinary surgeons who were sent the survey, 22% fully completed and submitted the questionnaire.
Some of the main findings included:
Around 40% of veterinary surgeons and over 40% of veterinary nurses said they had experienced concerns for their personal safety aside from catching Covid.
These safety concerns mostly related to client interactions at the practice either during the day or out-of-hours.
Many respondents experienced conflict between their personal wellbeing and professional role, and found it difficult to juggle their work and caring responsibilities.
Many respondents also said their mental health was adversely affected by the experience of working during the pandemic.
A large majority of respondents said they had personally seen an increase in caseload due to new animal ownership.
Lizzie Lockett, RCVS CEO, said: “While many of the results of the survey may not be especially surprising and confirm what we have already been told anecdotally, it is very important that we have this hard data to hand on the overall impact of the pandemic on individual members of the professions.
“These two reports complement the six surveys that we have conducted with veterinary practices on the economic impact of the pandemic to give us as clear and holistic a picture as possible about the challenges that the professions and the veterinary sector as a whole have faced since March 2020.
"This not only provides a useful historical snapshot, but builds an evidence base to inform future temporary changes should the pandemic continue into more waves, or should future such crises arise.
“The results of the two individual surveys make it clear it has been a tough time for the professions.
"A good proportion of respondents also acknowledged that positive developments have come from the past two years, including the way the profession has demonstrated remarkable resilience, flexibility and adaptability, as well as forging a stronger team spirit under such difficult circumstances.
“However, a large number of both vets and vet nurses who responded said that the experiences since March 2020 have left them feeling more pessimistic about veterinary work and their place within it.
"I would like to reassure members of the veterinary team that the RCVS is aware and understands.
"We tried throughout the pandemic to support the professions with relevant temporary guidance changes, and we are now working with a range of stakeholders on critical issues such as the workforce crisis, which has been in part caused by Covid.
"We are also developing tools, training and resources to support the professions, via our programmes such as RCVS Leadership and Mind Matters.”
The full coronavirus impact survey reports can be found at www.rcvs.org.uk/publications.
Sedaxylan 20 mg/ml contains the short acting alpha-2 agonist xylazine and is licensed for I/V administration.
It is also licensed for I/M administration in cattle; it has zero milk withdrawal and short one day meat withdrawal and sedation occurs in cattle within two minutes I/V and five to 10 minutes I/M.
Sedaxylan 20 mg/ml joins Dechra’s Nerfasin vet 100 mg/ml solution in the company’s anaesthesia and sedation range. Nerfasin vet also contains xylazine and is licensed for I/V administration for sedation and premedication prior to general anaesthesia in horses and cattle.
Alana McGlade, national sales manager at Dechra, said: “Dechra offers a comprehensive range of anaesthesia and sedation products allowing vets to customise protocols to the individual animal.
"Sedaxylan 20mg/ml and Nerfasin vet 100 mg/ml solution provide vets with flexible and convenient dosing options.”
Both Sedaxylan 20 mg/ml and Nerfasin vet 100 mg/ml are available in 25ml vials.
For more information, talk to your Dechra territory sales manager.
www.dechra.co.uk.
Zoetis says Lokivetmab targets and neutralizes canine interleukin-31 (IL-31), a cytokine associated with atopic dermatitis which sends the itch signal to the brain.
The company has submitted an application for marketing authorisation of the product, which is conditionally licensed in the US and Canada under the name Canine Atopic Dermatitis Immunotherapeutic, in the European Union.
The new data was presented at the 8th World Congress of Veterinary Dermatology (WCVD).
Supporting the efficacy of Lokivetmab in canine AD, Zoetis presented the results of a randomized, double-blind, placebo-controlled dose determination trial to evaluate efficacy of three doses of lokivetmab (0.125, 0.5 or 2.0 mg/kg) in providing relief from the clinical signs of pruritus (itching) and other clinical signs associated with atopic dermatitis in dogs.
Veterinary investigators at 15 clinics enrolled 245 client-owned, live-at-home dogs with chronic atopic dermatitis. Lokivetmab or a placebo was administered by subcutaneous injection on day 0, and efficacy was evaluated periodically over 56 days. Dog owners assessed their dog’s pruritus using a visual analog scale (VAS), and investigators assessed the associated skin lesions using Canine Atopic Dermatitis Extent and Severity Index-03 (CADESI-03) scores.
Lokivetmab, injected once subcutaneously, provided dose-dependent improvement in owner-assessed pruritus and clinician-assessed CADESI-03 scores for four to six weeks in dogs with atopic dermatitis.
Zoetis also presented results of a randomized, double-blind, placebo-controlled trial to assess the safety of lokivetmab at the nominal dose tested of 1 mg/kg (range, 1-3.3 mg/kg) in the treatment of canine atopic dermatitis. Veterinary surgeons evaluated 245 client-owned, live-at-home dogs with chronic, naturally-occurring atopic dermatitis. These dogs were randomized at a 2:1 ratio to receive two monthly injections of lokivetmab (162 dogs) or placebo on days 0 and 28.
No immediate hypersensitivity reactions were observed and there were no clinically important differences in clinical pathology results. No apparent adverse drug interactions were reported. Dogs studied were taking a wide variety of medications, which is important because multimodal therapy is commonly prescribed for dogs with atopic dermatitis. Adverse events were reported at a similar frequency between the groups.
The study1 was led by the RVC’s VetCompass programme and included 22,333 dogs whose health was followed for a year, during which 1,580 were recorded by the vet as overweight; roughly 1 in 14.
The authors point out that this figure is probably just the tip of the iceberg, because not every overweight pet will receive veterinary attention.
The study also found that certain breeds were especially prone to weight gain, including Pugs, Beagles, Golden Retrievers and English Springer Spaniels.
As well as showing that specific breeds were at differing risk, the study also highlighted that being neutered and middle-aged were additionally associated with increasing chances of dogs being overweight.
The main findings were:
Owners are encouraged to discuss their dog’s weight and lifestyle on every visit to their veterinary practice. This is of particular importance in the high-risk dogs identified in this study such as Pugs, Beagles, neutered and middle-aged dogs.
Camilla Pegram, VetCompass Epidemiologist at the RVC, and author of the paper, said: "This study has used the power of “big data” to robustly address the risk factors for obesity in dogs. Pugs, Beagles and Golden Retrievers were at greatest risk of obesity compared with crossbreeds.
"As well as genetics, management style could in part drive these breed predispositions. Whilst veterinary professionals and owners should focus efforts on obesity prevention strategies in all dogs, those identified at high-risk, such as Pugs, Beagles and Golden Retrievers, may need a more targeted approach."
Dr Eleanor Raffan, Associate Lecturer in Systems Physiology, at the University of Cambridge, and co-author of the paper, said:
“Where breed increases risk of a problem, it means genes are likely to be at least in part to blame and our previous work suggests that genetics drives a high appetite in some breeds. The bad news is that owners of food-obsessed dogs have to work much harder to keep their dogs at a healthy weight – the good news is that it can be done.”
Reference
Canaural contains fusidic acid, framycetin and nystatin for their antibacterial and antifungal effects against the most common organisms associated with otitis externa.
Fusidic acid has skin penetrating properties and is active against staphylococci and streptococci1. Framycetin is active against Gram negative species. Dechra says the combination of the two provides an enhanced antibacterial effect on the most common bacterial cause of canine otitis2.
Nystatin is active against malassezia and prednisolone helps to provide anti-inflammatory and anti-pruritic action.
Dechra Brand Manager Carol Morgan said: “The reintroduction of Canaural to the veterinary treatment market means that once again veterinarians have this reliable and effective treatment available to tackle one of the most common canine complaints.
"Canaural is a tried and tested product and a recent study showed that fusidic acid is highly efficacious against both methicillin sensitive and methicillin resistant strains of Staphylococcus pseudintermedius3. Canaural remains as relevant today as it has ever been."
Canaural comes in 15 ml and 25 ml bottle sizes and is now available in veterinary wholesalers.
References
Danilon is used to relieve the pain caused by musculoskeletal conditions, such as osteoarthritis (OA), bursitis, laminitis, and soft tissue inflammation.
Some oral NSAIDs have been shown to increase the risk of gastric irritation¹ - a particular concern when treating of chronic conditions.
However, Animalcare points to a study² in which horses given Danilon Gold showed a reduced number of ulcers and those that did appear were less severe.
The area of gastric mucosa affected was also five times less.
Animalcare says accurate administration is critical for clinical success.
To support this, Danilon Gold is presented in a coloured granule formulation and is now available in both 3g and 10g sachets.
The NOAH Code of Practice Committee, chaired by Mr Guy Tritton, has found Dechra Veterinary Products in breach of three items of the NOAH Code, following a complaint.
The complaint related to an advertisement and detailer promoting Felimazole with the wording "Are you taking a heavy-handed approach to hyperthyroidism?" and "with Felimazole, you don't have to!"
The Committee took the view that by implication this referred to Vidalta because Vidalta is the only other licensed oral treatment on the market for hyperthyroidism.
As a result, the Committee found both promotions in breach of Clause 4.3 because of the implication that Vidalta is less safe than Felimazole.
The Committee did not consider the promotions disparaged the manufacturer as there is no evidence to show it is unsafe.
The Committee also found that the table in the detailer (page 4) suggesting that one dosage of 5 mg per day of Felimazole has the same efficacy as two doses of 2.5 mg, (which is contrary to the dosing statement within the SPC: "If, for reasons of compliance, once daily dosing with a 5 mg tablet is preferable, then this is acceptable although reduced efficacy can be expected compared to a twice daily regime.") was misleading, contrary to Clause 4.3 of the Code.
Full details of the Committee's rulings are on the NOAH website at www.noah.co.uk/code. The full report of this particular case will be available shortly.
Propomitor can be used for the induction and maintenance of general anaesthesia for procedures lasting up to five minutes by the administration of incremental doses or as a constant rate infusion (CRI).
It can also be used for the induction of general anaesthesia where maintenance is provided by the inhalation of anaesthetic agents.
Animalcare Product Manager Kai Crawshaw said: "Propofol is the ‘go to’ solution for short-acting anaesthesia in many practices so we are delighted to add Propomitor, our new affordable propofol solution, to our range. It complements our already extensive anaesthetic toolkit, which offers options for analgesia, sedation, gaseous anaesthesia and recovery."
Propomitor is available in boxes of 5 x 20 ml bottles.
For more information, contact your Animalcare Territory Manager or Animalcare’s head office on 01904 487687.
Research commissioned by Bayer Animal Health has revealed that dogs really do look like their owners.
The research, which is being used to promote Drontal Bone, the company's new bone-shaped wormer, was conducted amongst 3,000 British dog-lovers. It found that the overwhelming majority of owners share at least one common physical attribute with their pet, whilst one in ten owners could be described as the spitting image of their dog, sharing six or more physical attributes:
As part of the campaign, Bayer has launched the Give Your Dog a Bone competition, a nationwide search to find the UK's "Top Dog". The competition is split into four video and photographic categories, with one open exclusively to dogs that have formed a special bond with their owner. Top dogs can enter via the competition website - www.giveyourdogabone.co.uk - where owners can upload photos, videos, and explain in under 100 words why they think their pet should win a Drontal 'Bonies' award.
Give Your Dog a Bone Judge Emma Milne MRCVS, said: "When dogs seem to have the same characteristics as their owners, it could be because people subconsciously choose a pet that resembles themselves. It is often found that more energetic breeds, such as s Red Setter have an owner who is sporty and most happy when taking their pet on long country walks, while a glamorous owner who enjoys grooming themselves might choose a dog which also requires lots preening, such as a Maltese Terrier. The Give Your Dog a Bone awards give us the chance to recognise the unique traits and talents that make dogs such an important part of our lives. With four very different categories, this competition will be wide open to dogs of all shapes, sizes and personalities!"
The RCVS Disciplinary Committee has directed that the name of a veterinary surgeon who formerly practised in Norwich should be removed from the Register, having found him unfit to practise veterinary surgery following his Crown Court conviction for fraud.
During the one-day hearing, the Disciplinary Committee heard how Francisco da Cruz had abused his position whilst practising as a veterinary surgeon at Hellesdon Vets, his then workplace in Norwich, by defrauding a insurance companies of around £10,000 with fictitious claims for veterinary treatment on non-existent pets.
Following an investigation by the City of London Police's Insurance Fraud Enforcement Department (IFED), Mr da Cruz was convicted on five counts of fraud by false representation on 21 February 2013 at the Old Bailey in London, and later sentenced to eight months' imprisonment (suspended for two years) and 200 hours of unpaid community work; he was also ordered to pay just over £10,000 in compensation and costs.
Although Mr da Cruz had left the UK for Brazil shortly after his sentencing and was therefore not present at the hearing, the Committee was satisfied that he was deliberately evading the disciplinary proceedings, rather than being genuinely unable to participate in them, and so the hearing proceeded in his absence.
First accepting the copy certificate of conviction against Mr da Cruz as true, the Committee then had no hesitation in concluding that these convictions rendered him unfit to practise as a member of the veterinary profession. It found that the five counts of fraud were deliberate crimes of dishonesty, committed over a significant period of time and for significant financial gain. He had abused his position as a veterinary surgeon and abused the trust which the insurers placed in him as a professional.
Chairing and speaking on behalf of the Committee, Professor Peter Lees, said: "The Committee has no real confidence that there is no significant risk of repeat behaviour from the Respondent. His conduct subsequent to the criminal proceedings gives it no confidence that he has reformed himself to the extent that he will in the foreseeable future be fit to return to practice. So far from satisfactorily completing his criminal sentence, it appears that the Respondent has deliberately gone abroad to avoid doing so."
Bearing in mind that the purpose of any sanction it imposed was not to punish Mr da Cruz, but to maintain public confidence in the profession and uphold proper standards of conduct within it, the Committee concluded that the convictions were too serious to allow any sanction other than removal from the Register.
The full details of the Committee's decisions are available on the RCVS website (www.rcvs.org.uk/disciplinary).